CANY
TEVA icon

Caxton Associates (New York)’s Teva Pharmaceuticals TEVA Stock Holding History

Caxton Associates (New York)’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,640
Closed -$192K – 674
2024
Q3 		$192K Sell
10,640
-19,067
-64% -$334K 0.01% 490
2024
Q2 		$483K Buy
+29,707
New +$458K 0.02% 347
2022
Q4 		– Sell
-60,525
Closed -$488K – 606
2022
Q3 		$488K Buy
60,525
+42,691
+239% +$377K 0.07% 241
2022
Q2 		$134K Buy
+17,834
New +$155K 0.01% 498
2018
Q2 		– Sell
-54,000
Closed -$923K – 475
2018
Q1 		$923K Buy
+54,000
New +$1.05M 0.05% 195
2017
Q4 		– Sell
-13,300
Closed -$234K – 520
2017
Q3 		$234K Buy
13,300
+300
+2% +$6.75K 0.01% 461
2017
Q2 		$432K Buy
13,000
+800
+7% +$24.8K 0.02% 383
2017
Q1 		$391K Buy
+12,200
New +$416K ﹤0.01% 313
2015
Q1 		– Sell
-19,500
Closed -$1.12M – 199
2014
Q4 		$1.12M Buy
+19,500
New +$1.09M 0.09% 109
2014
Q3 		– Sell
-7,200
Closed -$377K – 253
2014
Q2 		$377K Buy
7,200
+1,300
+22% +$66.4K 0.02% 151
2014
Q1 		$312K Sell
5,900
-37,000
-86% -$1.71M 0.02% 149
2013
Q4 		$1.72M Buy
+42,900
New +$1.69M 0.05% 127
2013
Q3 		– Sell
-62,300
Closed -$2.44M – 225
2013
Q2 		$2.44M Buy
+62,300
New +$2.43M 0.12% 106

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Caxton Associates (New York)'s TEVA Position: Q4 2024 in Review

Caxton Associates (New York) sold out of Teva Pharmaceuticals (TEVA) in Q4 2024, closing a stake of 10,640 shares — an estimated $192K sold.

Caxton Associates (New York) first reported a position in TEVA in Q2 2013 and held it in 13 quarters. The position peaked at $2.44M in Q2 2013. 583 funds tracked by Wall St. Rank hold TEVA as of Q4 2024.

  • Caxton Associates (New York) reported no remaining Teva Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Caxton Associates (New York) sold 10,640 Teva Pharmaceuticals shares in Q4 2024, an estimated $192K.
  • Caxton Associates (New York) first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 13 quarters.
  • Caxton Associates (New York)'s Teva Pharmaceuticals position peaked at $2.44M in Q2 2013.
  • 583 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2024.

Based on Caxton Associates (New York)'s 13F filing for Q4 2024, filed 14 Feb 2025.